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Abstract
& We tested the hypothesis that age-related time production
deficits are dopamine-mediated. The experiment was con-
ducted double-blind, and with random assignment of 32 healthy
aged and 32 healthy young participants to either inert placebo
or levodopa (200 mg) groups. The procedure included training
participants to produce two target time intervals (6 and 17 sec)
in separate blocks, drug/placebo administration, a 1-hr delay,
and then delayed free-recall time production retesting without
feedback. Participants also performed a speeded choice
reaction time (RT) task, as a control for potential dopaminergic
and aging effects on attention and psychomotor speed. Results
indicate that during retesting, aged participants show duration-
dependent timing errors that are larger than those shown by the
young participants. Levodopa administration yielded length-
ened time production of both target intervals. The aging and
levodopa effects did not interact. Also, aging slowed RT and
increased RT variability, but levodopa had no effect on the RT.
These results suggest that at this dosage and under these
specific conditions, timing is dopamine-mediated but the effect
of aging on time production is not. Moreover, the levodopa
timing effect cannot be attributed to the effects of dopaminergic
function on psychomotor speed. &
INTRODUCTION
There is an increasingly broad literature demonstrating
that aging is associated with impaired interval timing
abilities. These experiments have taken place during a
period of growing empirical and theoretical understand-
ing of the neuroanatomical, pharmacological, and cog-
nitive underpinnings of interval timing (Ivry & Spencer,
2004; Gibbon, Malapani, Dale, & Gallistel, 1997). Among
these findings are demonstrations of specific dopamine
(DA)-dependent timing impairments in Parkinson’s dis-
ease (PD) patients, as well as animal studies indicating
the involvement of the dopaminergic systems. Also
relevant are studies indicating that age-related impair-
ment to (nontemporal) memory and attention stem at
least in part from loss of DA-dependent frontal function
(Braver & Barch, 2002). These facts, combined with
certain similarities between the age and PD-related
timing impairments (Rakitin, Stern, & Malapani, 2005;
Malapani, Rakitin, Fairhurst, & Gibbon, 2002), motivated
the current study examining the effects of a DA-based
pharmacological intervention on age-related time pro-
duction impairment.
Time production refers to the act of matching re-
sponse latency to the duration of a remembered target
interval in discrete trials.1 Time production by healthy
young subjects has two characteristic psychophysical
qualities, accuracy and scalar variability (Rakitin, 2005;
Rakitin, Gibbon, et al., 1998; Ivry & Hazeltine, 1995;
Wearden & McShane, 1988). Accuracy refers to the
absence of systematic deviations in average response
latency from the target intervals. Scalar variability refers
to the tendency for intraindividual response latency
variability measured by the standard deviation to in-
crease in proportion to the average response latency.
The standard information processing model of this and
other timing behaviors includes a time basis2 (i.e., the
apparatus for the subjective representation of currently
elapsing intervals), memory, and decision stages (Zakay
& Block, 1997; Gibbon, Church, & Meck, 1984; Gibbon
& Church, 1983; Treisman, 1963), collectively referred to
as the ‘‘internal clock.’’ The time basis consists of a
variable speed pacemaker, a switch, and an accumulator.
The accumulator serves as a ‘‘sensory store’’ or ‘‘work-
ing memory’’ for time, the activity of which increments
with real time if attention is directed toward time,
closing the switch, and allowing pacemaker pulses to
increment the accumulator. Intervals marked as relevant
by feedback or reinforcement enter into ‘‘reference’’
memory, for comparison to the current accumulator
value and the decision as to whether or how to respond.
Although timing relies on the functioning of many
neurochemical systems (Meck, 1996), animal studies
have implicated dopaminergic neurotransmitter systems
in the control of two aspects of the time basis, the
pacemaker and the switch. Indirect DA agonists such as1Columbia University, 2New York State Psychiatric Institute
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methamphetamine (Maricq & Church, 1983; Meck, 1983;
Maricq, Roberts, & Church, 1981) speed up the pace-
maker, whereas DA antagonists such as haloperidol
(Meck, 1983, 1986; Maricq & Church, 1983) slow down
the pacemaker. These same drugs have contrasting
effects on animals’ ability to selectively attend to timing
stimuli (Buhusi & Meck, 2002; Santi, Weise, & Kuiper,
1995). Specific D2 receptor agonists such as quinpirole
only affect attention to time (Stanford & Santi, 1998;
Frederick & Allen, 1996). Whether a particular DA agent
affects both pacemaker speed and attention may depend
on whether the drug has affinity for the D1 DA receptor
in addition to the D2 receptor (Stanford & Santi, 1998;
Frederick & Allen, 1996; Meck, 1986).
Pharmacological studies of timing with healthy young
human participants are fewer in number and primarily
use temporal discrimination tasks (i.e., judging a stimu-
lus as longer or shorter in duration than a standard
interval). These studies generally support the models
derived from the animal experiments. For example,
haloperidol reduces the precision of temporal judg-
ments, an effect consistent with reduced pacemaker
speed (Rammsayer, 1989, 1994, 1997, 1999). Drugs which
act to either increase (e.g., levodopa) or decrease (e.g.,
AMPT) DA in the striatum had no effect on short interval
discrimination (Rammsayer & Vogel, 1992; Rammsayer,
1989), suggesting that DA receptor activity rather than
DA levels were responsible for the timing effects. These
studies also suggested that discrimination and estimation
of longer (>0.5 sec) intervals is sensitive to drugs (e.g.,
remoxipride) that primarily affect the mesolimbocortical
DA, whereas very brief interval discrimination is selec-
tively impaired by haloperidol, which affects the meso-
striatal DA system (Rammsayer, 1994, 1997). Evidence
that benzodiazepine and cholinergic agonists that affect
memory function also affect timing of these longer
intervals suggests a role for DA in the modulation of
temporal memory (Rammsayer, 1997, 1999).
Parkinson’s disease provides an opportunity for study-
ing the effects DA has on timing because it produces DA
depletion in the striatum (Kaasinen & Rinne, 2002; Agid
et al., 1989; Hornykiewicz, 1989). Most convincing are
those studies that have directly linked DA to deficits
in time discrimination (Pastor, Artieda, Jahanshahi, &
Obeso, 1992), time production (Malapani, Deweer, &
Gibbon, 2002; Malapani et al., 1998; Pastor, Artieda, et al.,
1992), and repetitive tapping (O’Boyle, Freeman, &
Cody, 1996; Pastor, Jahanshahi, Artieda, & Obeso,
1992; cf. Diedrichsen, Ivry, & Pressing, 2003 for an
alternative view) by comparing PD patients on and off
DA replacement therapy (i.e., levodopa). In some cases,
DA-mediated timing errors are consistent with a slowed
pacemaker (e.g., Pastor, Artieda, et al., 1992). However,
Malapani and Rakitin (2003) and Malapani, Deweer, et al.
(2002) demonstrated DA-related timing deficits related
to temporal memory encoding and retrieval. The PD
results are congruent with the pharmacology studies to
the extent that they implicate both pacemaker and
temporal memory systems. They differ in that the use
of levodopa as the active agent implicates striatal DA
levels in the control of temporal behavior.
In lines of research unrelated to the DA hypothesis,
many studies report that aging adversely affects timing. A
meta-analysis of studies of timing and aging (Block,
Zakay, & Hancock, 1998) indicated that verbal estima-
tions grew shorter with age, verbal productions grew
longer with age, and temporal production was unaffect-
ed by age. These effects were attributed to age-related
decrease in attention to time and the corresponding
effect on the switch. More recent reports confirm the
general finding of attention-mediated timing problems
in aging (Lustig & Meck 2001; Craik & Hay, 1999;
Vanneste & Pouthas, 1999), and also report age-related
deficits in time production (Rakitin, Stern, et al., 2005;
Perbal, Droit-Volet, Insingrini, & Pouthas, 2002; Craik &
Hay, 1999). Degraded temporal memory in aging has
also been inferred. Time reproductions under distrac-
tion shortened with age, and were associated with
poorer working memory performance (Perbal et al.,
2002). Other studies have found progressively noisy
encoding of temporal values with increasing age
(McCormack, Brown, Maylor, Darby, & Green, 1999;
Wearden, Wearden, & Rabbitt, 1997), and time produc-
tion errors restricted to delayed free recall (Rakitin,
Stern, et al., 2005; Malapani, Rakitin, et al., 2002).
No studies exist directly linking DA function to age-
related timing deficits. However, there is ample evidence
that DA function declines with age. Postmortem studies
have demonstrated that DA in the striatum decreases
with age (e.g., Haycock et al., 2003) at approximately
40% of the rate found in PD (Agid et al., 1989), and
with a more even distribution across the striatum
(Hornykiewicz, 1989). PET imaging of the DA system
indicates normal age-related loss of D1 (Suhara et al.,
1991) and D2 (Volkow et al., 1996) receptors across the
brain, but especially in the striatum and frontal cortex
(Kaasinen & Rinne, 2002; Kaasinen et al., 2000; Suhara
et al., 1991). PET imaging studies have also linked age
reductions in D2 to decreased executive and motor
function (Kaasinen & Rinne, 2002; Backman et al.,
2000; Volkow et al., 1998). Age-related deficits in cog-
nitive function have been treated with DA agonists
(Arnsten, Cai, Steere, & Goldman-Rakic, 1995; Ollat,
1992), supporting the functional imaging findings.
The above review establishes several facts: (1) timing
relies on DA, (2) DA declines in aging, and (3) timing in
aging is abnormal. From these facts, the question arises
as to whether age-related timing problems stem from
loss of dopaminergic function.
In order to test this hypothesis, we chose to examine
the effects of levodopa on delayed free-recall peak-
interval (PI) time production. The motivation for the
choice of procedure is the apparent similarity in impair-
ments observed in both PD (Malapani, Deweer, et al.,
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2002) and healthy aged (Rakitin, Stern, et al., 2005)
participants in delayed free-recall PI performance, sug-
gesting a shared information processing basis (Rakitin,
Stern, et al., 2005; Malapani & Rakitin, 2003). We theo-
rize that the duration-dependent errors shown by both
groups—the tendency to overproduce the shorter of
two intervals while underproducing the longer interval
to a greater (as in PD) or lesser (as in healthy aging)
extent—stem from alterations to the accumulator (i.e.,
working memory). These alterations cause the accumu-
lator value to increase slowly for short intervals but
to accelerate as intervals elapse (Shea-Brown, Rinzel,
Rakitin, & Malapani, in press; Malapani & Rakitin, 2003).
As a result, subjective time lags behind real time for
short intervals and leads real time at longer values pro-
ducing the characteristic duration-dependent timing
errors. Regardless of the proposed cognitive mechanism
(for an alternative proposal, see Meck & Benson, 2002;
Mattle & Meck, 2000), further similarity between the PD
and aging effects can be established by demonstrating
that the aging effect is DA dependent.
Another advantage of the delayed free-recall PI pro-
cedure is its complexity. The requirement that partic-
ipants retain and then produce two target seconds-long
intervals without the advantage of feedback adds tem-
poral memory and attention requirements that may
make the task more sensitive to DA function than the
time perception task previously shown to be insensitive
to levodopa (Rammsayer, 1989).
The choice of levodopa as the DA agent in this
experiment reflects the fact that levodopa fully reverses
the PD impairment (Malapani, Deweer, et al., 2002) and
medicated PD patients performed better than their age-
matched controls, potentially indicating a reversal of a
baseline aging effect (Malapani, Rakitin, et al., 2002). The
200-mg dose of levodopa was chosen to exceed the dose
that previously failed to alter time perception thresholds
(Rammsayer, 1989), and to generate tolerable side effects
in both young (Hasbroucq, Tandonnet, Micallef-Roll,
Blin, & Possamaı¨, 2003; Micallef-Roll, Rihet, Hasbroucq,
Possamai, & Blin, 2001) and old (Newman, LeWitt, Jaffe,
Calne, & Larsen, 1985) participants. Our hypothesis is
that administration of levodopa to participants dur-
ing the retention interval will attenuate the duration-
dependent timing errors observed in aged individuals.
This hypothesis depends on the assumption that the
aging deficit stems from reduced DA levels, which would
be increased by levodopa (Misu, Goshima, Ueda, &
Okamura, 1996). In contrast, the increased DA levels
produced by levodopa would have little effect if the
deficit was related instead to reduced receptor density
(e.g., Kaasinen & Rinne, 2002).
Levodopa also produces a measurable decrease in
reaction time (RT: Hasbroucq et al., 2003; Micallef-Roll
et al., 2001). These findings regarding the effects of
levodopa on psychomotor speed motivated us to in-
clude a choice RT task as a control. That is, if levodopa
affects both RT and time production in the same direc-
tion, the effects would be attributable to changes in
psychomotor speed, rather than to the specific effects of
levodopa on time production.
RESULTS
Side Effects
Of the 16 elderly subjects who took levodopa, 7 (44%)
reported mild nausea. Of these, 3 (43%) experienced it
only during the break before testing, and 4 (57%)
experienced it during testing. Of the 16 young subjects
who took levodopa, 7 (44%) reported mild nausea. Of
these, 4 (57%) experienced it only during the break
before testing, and 3 (43%) experienced it during test-
ing. In addition, one young control participant reported
nausea during testing due to an unrelated stomach
ailment.
Time Production
Individual participants’ (symbols) and group mean
(lines) time production accuracy (i.e., MD) data are
presented in Figure 1. For all four groups and both target
intervals, the solid lines represent the group mean
baseline production performance, which was very close
to the target intervals’ duration, indicating accurate
baseline time production, on average. The main effect
of duration was significant [F(1,60) = 2260.58, p < .0001].
There was also a significant Session  Duration interac-
tion [F(1,60) = 1956.53, p < .0001], reflecting the fact
that during testing all four groups overproduced the
short interval, and three of the four groups underpro-
duced the long interval, relative to baseline.
Comparing the dashed lines in the two right panels to
the dashed lines in the two left panels, one can see that
group mean time productions during the retesting
session are longer following administration of levodopa
compared to placebo. The size of this levodopa-induced
overproduction is 0.87 sec, averaged over target intervals
and age groups, and subtracting baseline performance.
This effect corresponds to a significant Session  Drug
group interaction [F(1,60) = 4.49, p < .05]. The main
effect of drug group was also significant [F(1,60) = 4.86,
p < .05]. Also evident in Figure 1 is the relatively even
distribution of values associated with individuals with
nausea during the retesting session. Excluding these
individuals from the analysis increased the magnitude
of the levodopa effect to 1.05 sec, and significance of
both the Session  Drug group interaction [F(1,52) =
5.12, p < .05] and the main effect of drug group
[F(1,52) = 6.03, p < .05]. In the analysis that subdivided
the two levodopa groups into those who did and did not
experience nausea at any point during the experiment,
the only significant effect was that of session [F(1,28) =
4.60, p < .05]. It is therefore unlikely that the levodopa
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effect is mediated by the drug side effects, rather than
drug action on the DA system.
Comparing the dashed lines in the two top panels to
the dashed lines in the two bottom panels, one can see
that the aged group’s mean time productions during the
retesting session were shorter than the young group’s
means, by about 0.83 sec, averaged over target interval
and drug group, and subtracting the baseline data. This
effect corresponds to a significant Session  Age group
interaction [F(1,60) = 4.13, p < .05]. Excluding the indi-
viduals that experienced nausea during retesting from
the analysis increased the magnitude of the aging effect
to 1.04 sec, and significance of the Session  Age group
interaction [F(1,52) = 5.33, p < .05]. The aged group’s
means for production of the two intervals were also
closer together than those of the young group’s by about
1.16 sec. However, the Session  Duration  Age group
interaction was marginal [F(1,60) = 3.21, p = .078], until
the individuals with nausea during testing were removed
from the analysis [F(1,52) = 4.65, p < .05].
It is important to note that the Session  Age group 
Drug group interaction was not significant either with
[F(1,60) = 0.38] or without [F(1,52) = 0.55] those indi-
viduals who experienced nausea during the retesting
session.
Table 1 presents the group mean time production
NPCV (the nonparametric coefficient of variation) data
by session and target interval duration. The NPCV mea-
sures the spread of responses relative to the median
response time, and is equal for different target intervals
when the scalar property applies. There were three
significant effects in these data. The NPCVs of short in-
terval productions were 1.3% greater than NPCVs of long
interval production [F(1,60) = 22.28, p < .0001], a small
but reliable violation of the scalar property. Retesting
session NPCVs were 1.6% greater than baseline session
NPCVs [F(1,60) = 26.21, p < .0001]. There was also a
significant Session  Duration  Drug group interaction
[F(1,60) = 4.57, p < .05]. This was a full crossover
interaction, and the biggest increases in NPCV between
Figure 1. Time production
MD data. The four panels
each contain data for all
16 participants in one of the
four groups, plus the group
means. The four symbols in
each column of each panel
indicate one participant’s
mean MDs for the 6-sec
baseline (lower circles), the
17-sec baseline (upper circles),
6-sec testing (lower triangles),
and 17-sec retesting (upper
triangles) sessions. Participants
that experienced nausea
during the retesting sessions
are denoted with small
symbols. Within each panel,
the participants are sorted
from left to right in order of
increasing 17-sec retesting
session MD. The solid lines are
the group means for the
baseline sessions and the
dashed lines are the group
means for the retesting
sessions.
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baseline and retesting sessions were in the two placebo
groups’ 6-sec productions (2.2%), and the two levodopa
groups’ 17-sec productions (2.4%). In contrast, increases
in the two placebo groups’ 17-sec productions (1.2%)
and the two levodopa groups’ 6-sec productions (1.1%)
were smaller.
Removing participants who experienced nausea dur-
ing the retesting session produced similar effects for
duration [F(1,52) = 19.78, p < .0001], session [F(1,52) =
24.14, p < .0001], and the Session  Duration  Drug
group interaction [F(1,52) = 4.18, p < .05]. Considering
only the levodopa groups, the effects of session
[F(1,28)= 18.78, p < .05] and duration [F(1,28) =
17.16, p < .05] were significant, and the Session 
Duration interaction was marginal [F(1,28) = 3.04,
p = .092]. All effects of the presence or absence of
nausea were nonsignificant.
Choice Reaction Time
Individual participants’ (symbols) and group mean
(lines) MD RT data are presented in Figure 2. Aged
participants were 206 msec slower than young partic-
ipants, a significant main effect of age [F(1,60) = 41.86,
p < .0001]. The Session  Age group interaction was
significant [F(1,60) = 4.98, p < .05], reflecting a 55-msec
improvement in the aged participants’ speed between
the baseline session and the retesting session that was
absent in the young participants. The main effect of
session [F(1,60) = 22.28, p < .05] was also significant.
The absence of drug group effects renders side effects
analyses unnecessary.
Table 2 presents the choice RT NPCV data. Aged par-
ticipants’ NPCVs were significantly higher than young par-
ticipants’ NPCVs [F(1,60) = 5.56, p < .05] by about 3.8%.
There was a tendency for the NPCVs to be lower in the
retesting session than in the baseline session [F(1,60) =
3.89, p < .0531]. There were no significant effects on
%COR, and the cell means ranged from 96.6% to 98.3%.
Correlations between Time Production
and Reaction Time Performance
Table 3 presents the correlations between the difference
in MD RT between sessions and the difference in MD
time production between sessions. This table includes
correlations among all participants (excluding those that
felt nauseous during the retest session) as well as the
various subgroupings of participants. None of the corre-
lations is significant. Therefore, we cannot reject the null
hypotheses that the difference in MD RT between
sessions is independent of the difference in either short
or long interval MD time production between sessions,
for participants grouped by age, drug, or the interaction
of the two.
DISCUSSION
In this experiment, a successful test of the hypothe-
sis that an age-related time production deficit is DA-
mediated required three positive outcomes. First, we
had to demonstrate that the age-related effect occurs
in this procedure. That was accomplished by demon-
strating a significant Age  Session and Age  Session 
Duration interaction effect on the MD. Second, we had
to demonstrate that levodopa had an effect on time
production. The Session  Drug group interaction ef-
fect on the MD demonstrated this effect. Third, we had
to demonstrate an interaction of levodopa and aging
effects, that is, a Session  Age group  Drug group
interaction. However, that effect was not significant,
and so we cannot reject the null hypothesis that the
age-related time production effect observed in this
experiment is independent of the alteration in DA func-
tion caused by a 200-mg dose of levodopa.
The successful demonstration of aging and levo-
dopa effects in the current experiment (discussed in
more detail below) created the necessary conditions
for testing our main hypothesis, that the aging effect is
DA-mediated. The absence of a significant interaction
between the two effects instead supports the null hy-
pothesis of independence between the effects. Failing
to reject the null never rules out the possibility that the
alternative is true. For example, a larger dose of levodo-
pa, or another agent altogether, may result in a detect-
able interaction, where the current agent did not. We are
especially interested in testing the effects of direct DA
agonists, which may be more efficacious in reversing an
age-related deficit stemming from reduced receptor
density. Agents that may affect the many other neuro-
Table 1. Time Production NPCV Data, with Standard Errors
Baseline Sessions Retesting Sessions
Age Group Drug Group 6 sec 17 sec 6 sec 17 sec
Aged Placebo 9.02 ± 1.03 7.99 ± 0.86 9.80 ± 1.02 8.47 ± 0.84
Aged Levodopa 9.05 ± 1.14 6.78 ± 0.83 10.03 ± 1.27 8.89 ± 1.61
Young Placebo 7.16 ± 0.93 6.83 ± 0.74 10.72 ± 1.22 8.71 ± 1.00
Young Levodopa 6.76 ± 0.78 5.01 ± 0.50 7.98 ± 0.70 7.61 ± 0.83
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chemical systems shown to affect timing, including the
cholinergic system (Meck, 2002; Meck & Church, 1984),
may also be good candidates. In addition, a failure to
reject a null hypothesis may stem from a lack of task or
design sensitivity. However, the current study task and
design have now been employed to demonstrate the
effects of levodopa on PD patients, as well as healthy
young and old participants, and to demonstrate and
replicate the basic effects of aging on time production,
providing ample evidence of its sensitivity.
The aging effect reported here replicates that observed
in a previous study (Rakitin, Stern, et al., 2005) in two
important ways. First, the effect occurs only during the
delayed free-recall retesting session. Second, the direc-
tion of the production errors depended on the duration
of the target time interval. That is, aged individuals over-
produced the short interval and underproduced the long
interval. In the previous study, the aging effect was
somewhat smaller in magnitude on average (aged partic-
ipants overproduced the short interval but accurately
timed the long interval), but was more reliable. The
difference between the studies may reflect random var-
iability or differences in the procedures. The most obvi-
ous difference in the procedures is the duration of the
retention interval between training and retesting—1 hr in
the current study and 24 hr in the previous study. A future
study that parametrically varies the retention interval
could resolve its effect on the magnitude and reliability
of age-related time production errors.
The evidence for a levodopa-induced time production
effect contrasts with the negative result obtained in the
Table 2. Choice RT NPCV Data, with Standard Errors
Age Group Drug Group Training Testing
Aged Placebo 22.74 ± 5.92 20.63 ± 7.83
Aged Levodopa 22.92 ± 6.59 21.10 ± 7.85
Young Placebo 20.97 ± 13.11 19.02 ± 6.25
Young Levodopa 17.04 ± 4.35 15.34 ± 3.42
Figure 2. Choice RT MD
data. The four panels each
contain data for all
16 participants in one of the
four groups, plus the group
means. The two symbols in
each column of each panel
indicate one participant’s
mean MDs for the baseline
(circles) and retesting
(triangles) sessions. The
ordering of participants from
left to right is the same as in
Figure 1. The solid lines are the
group means for the baseline
sessions and the dotted lines
are the group means for the
retesting sessions.
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only other study of the effects of levodopa on timing in
healthy participants (Rammsayer, 1989). Three impor-
tant differences between the current and previous study
may account for the discrepancy. First, the previous
study used a lower (100 mg) dose of levodopa.3 There
are no existing dose–response studies of the effects of
levodopa on performance in healthy individuals, but two
studies noting positive levodopa effects on RT used the
current, higher (200 mg) dose (Hasbroucq et al., 2003;
Micallef-Roll et al., 2001). Second, the current study
tested much longer intervals than the previous study.
There is psychophysical (Ivry & Spencer, 2004; Gibbon
et al., 1997), pharmacological (Rammsayer, 1994, 1997),
and brain imaging (Lewis & Miall, 2003) evidence to
suggest that timing of shorter (i.e., <1 sec) and longer
intervals have different information processing require-
ments. Long interval timing puts greater demands on
temporal memory and temporal attention. These pro-
cesses are known to be DA mediated (e.g., Malapani,
Deweer, et al., 2002; Meck & Benson, 2002) and so the
current experiment may have been more sensitive to DA
effects. Third, this experiment required participants to
retain temporal memories for at least an hour, whereas
Rammsayer’s study did not. This retention interval adds
long-term (or reference) memory processing to the
task, which may have further increased the task’s sensi-
tivity to DA.
The effect of levodopa in this experiment was to cause
participants to respond too late relative to the target
time interval. In terms of the standard information
processing model of timing discussed in the Introduc-
tion, overproduction during testing implies that subjec-
tive time is flowing slower in the retesting session (after
drug administration) than during the baseline session,
when the memory for the standard interval is estab-
lished. One possibility is that this effect reflects psycho-
motor slowing not restricted to temporal cognition.
However, this effect was specific to timing to the extent
that levodopa did not produce lengthening of the RT in
the choice RT task, nor was there an association be-
tween individuals’ timing and RT performance. These
two facts suggest that the effects of levodopa are specific
to time production. However, this suggestion is tem-
pered by the possibility that the null effect of levodopa
on the RT reflects a lack of task sensitivity rather than an
absence of an effect on psychomotor speed. Such a lack
of sensitivity could explain our failure to replicate past
positive findings (Hasbroucq et al., 2003; Micallef-Roll
et al., 2001).
Several aspects of the internal clock model can ac-
count for the observed levodopa effect on time produc-
tion. For example, if levodopa slows the pacemaker,
inflates the remembered interval upon retrieval from
long-term memory, or delays the closing of the switch
when participants direct attention to time at the begin-
ning of the trial, then participants will respond too late. It
is possible to distinguish between some of these possi-
bilities. Both pacemaker speed and memory translation
effects can produce errors that are proportional to the
duration of the target interval and preservation of the
scalar property of timing variability (Malapani, Deweer,
et al., 2002; Gibbon et al., 1984; Gibbon & Church, 1983;
Meck, 1983). In contrast, switch effects are associated
with errors that are independent of the target interval
duration (Meck & Church, 1983) and may cause viola-
tions of the scalar property if the interval is sufficiently
short (Rakitin, 2005). In the current data, the errors for
the short interval and long interval are approximately
equal, lending support to the delayed-switching hypoth-
esis. The complex interaction evident in the variability
data is not diagnostic of either effect, and is more likely
indicative of baseline differences between the groups
than the differential effects of levodopa. Taken together,
the data favor the notion that application of levodopa
slows the processes of switching attention to time.
Recent studies with rats of the effects of DA agonists
on attention (Buhusi & Meck, 2002) provide additional
support for the delayed-switching hypothesis. When
administered methamphetamine, rats tend to restart
timing following an interruption in a timing stimulus.
The DA antagonist haloperidol produced the opposite
effect, and rats were able to readily switch attention
between timing and not timing as the interruption
began, and then switch back again when the gap ended.
These results were interpreted to indicate that DA
agonists could reduce attention to time—a finding
consistent with the current results. In contrast, studies
of pharmacological effects on pacemaker speed (Meck,
1983, 1986) indicate that DA agonists increase the speed
Table 3. Correlations between the Retest Session RT
and Time Production Individual Medians Expressed as
Difference from Baseline, Excluding Participants with
Nausea during the Retesting Session
Old Young Old + Young
Levodopa n 12 13 25
Short .36176 .35262 .31474
Long .14978 .25756 .06191
Control n 16 15 31
Short .11006 .05791 .03787
Long .06445 .45519* .30162
Levodopa + Control n 28 28 56
Short .17331 .15258 .13848
Long .03011 .11582 .12079
Note: Rows labeled ‘‘n’’ indicate the number of subjects included in
that condition. Correlations (Pearson’s R) in the rows labeled ‘‘Short’’
and ‘‘Long’’ are between the RT and time production of the short
interval and long interval, respectively. None of these correlations is
significant at the p < .05 level.
*Indicates p < .1 level.
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of the internal pacemaker. Such results contradict the
current data, which are consistent with a decrease in
pacemaker speed after administration of levodopa.
Another important comparison is between the current
results and the DA-mediated effects on temporal mem-
ory encoding observed in PD patients. PD patients
trained off levodopa and then tested on medication (in
an experiment very similar to the current one but with a
24-hr retention interval) overproduced two target inter-
vals equal in duration to those used here (Malapani,
Deweer, et al., 2002). The PD encoding effect is scalar in
both magnitude and variability. Although errors of this
sort can also be due to changes in pacemaker speed or
long-term memory for duration, as discussed previously,
the authors preferred to attribute this effect to a distor-
tion in memory encoding. There were two reasons. First,
it was assumed that the dysfunctional operation must
have occurred during the baseline session when patients
were in a DA-depleted state, and memory encoding is
the most obvious candidate for producing an effect
during a later retesting session when relearning of the
interval was impossible. Second, the effect was in the
opposite direction to that associated with DA pacemaker
speed effects (Meck, 1983, 1986).
The similarities between the PD encoding effect and
the current levodopa effect seem to end with the fact
that both effects are characterized by overproduction of
two intervals. Differences include the approximately
constant errors in production of the two intervals and
the association between the error and an increase in DA
activity above baseline in the retesting session of this
experiment. However, a few additional facts should be
considered before entirely dismissing the comparison.
First, medicated PD patients perform better than their
age-matched controls (Malapani, Rakitin, et al., 2002), in
terms of both accuracy and variability. This suggests that
medicated PD patients may be demonstrating the effects
of increased DA during the retesting session. Second,
slowed pacemaker speed was considered as a possible
mechanism in both cases, but was dismissed on the basis
of indirect evidence. Third, discriminating between con-
stant and proportional effects can be difficult when the
effects are small, as was the case here. Considering these
three facts together, it is conceivable that a relative
increase in DA activity between training and testing,
resulting in a slowed pacemaker during testing, could
explain both effects if two additional facts were to come
to light. First, some physiological mechanism for pro-
ducing paradoxical DA agonist effects would have to be
demonstrated. Some evidence for this already exists in
the U-shaped dose–response curves sometimes associ-
ated with DA agonists (Misu et al., 1996; Arnsten et al.,
1995), but these effects have not been shown in timing
experiments aimed at understanding pacemaker speed.
Second, future timing experiments with larger doses of
levodopa or other DA agonists would have to demon-
strate proportional timing errors with scalar variability.
Our tact in interpreting the results of the present
experiment was to use SET to obtain as specific an
inference as possible given the limitations of the exper-
iment. However, these results can be interpreted more
generally in two important ways. First, it is possible to
conclude that levodopa affects attention to time without
referring to a pacemaker–accumulator system. Several
timing theories (e.g., Thomas & Weaver, 1975; Wing &
Kristofferson, 1973) note that understanding the totality
of timing psychophysics requires considering the rela-
tions between timing and nontiming processes in gen-
eral. The Thomas and Weaver model, in particular,
makes many of the same predictions as the switching
model discussed here by assuming that attention is
shared between visual and temporal processing, but
does not make any reference to the switch.
Second, our expansive definition of the internal clock
to include attention and memory components raises the
question of the extent to which the phenomena re-
ported in the present experiment are domain-specific
timing effects. Our view is that in the absence of specific
controlled experiments to test the hypothesis that tem-
poral cognition shares information processing compo-
nents with the processing of information from other
domains, the data from the present experiments should
be interpreted narrowly. However, as noted previously,
both aging and dopaminergic drugs produce cognitive
changes in a variety of domains. Thus, we must consider
the possibility that the present effects are one instance
of general aging and DA phenomenon made apparent by
the complex nature of PI timing of relatively long
intervals. More specifically, the suggestion that levodopa
affects temporal attention by altering the operation of
the switch component of the internal clock’s time basis
should not be taken to imply that the effects of levodopa
on attention are specific to timing. On the contrary, that
DA affects attention is a central component of a major
theory of age-related cognitive decline (Braver & Barch,
2002). The current experiment does not provide an
opportunity to test the association between DA and
attention in general because the attention demands of
the current RT task are minimal. A future experiment on
DA and timing that includes an RT task that requires
sustained attention might prove useful in this regard.
METHODS
Participants
Thirty-two young participants were recruited from flyers
posted on the campus of the Columbia University Med-
ical Center. Thirty-two elderly participants were re-
cruited from flyers posted on the campus of the
Medical Center and through telephone contact using
subject databases from previous studies. Interested par-
ticipants were screened on the telephone or through
e-mail for neurological or psychiatric disorders, use of
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psychoactive medication, and conditions that could po-
tentially incur a health risk with the study drug, specifi-
cally glaucoma and melanoma. A neurologist at the
testing site further screened the participants for medical
history and current medical conditions. All participants
assessed with the motor subscales of the Unified Parkin-
son’s Disease Rating Scale (UPDRS; Richards et al., 1991)
and were determined to be free of extrapyramidal signs
(i.e., no subscale scores greater than 1). All participants
were determined to be free of dementia, having obtained
above 125 on the Mattis Dementia Rating Scale (DRS;
Mattis, 1988) and above 45 on the modified Mini-Mental
Status Exam (mMMSE; Stern, Sano, Paulson, & Mayeux,
1987). Table 4 provides additional details about the
participants.
The young and old participants were assigned ran-
domly to receive either levodopa or a placebo control
(see Procedures below). The final design therefore
includes four groups of 16 participants: old/control,
old/levodopa, young/control, and young/levodopa.
Apparatus
Data from all the participants were collected using a
Macintosh G3 iBook laptop computer with a 13.1-in.
color monitor. Participants were tested in rooms dedi-
cated to running clinical experiments that were located
in the Irving Center for Clinical Research at the Presby-
terian Hospital of the Columbia University Medical
Center. Stimulus presentation and response acquisition
in the RT task were driven by the Psyscope experimental
design package (Cohen, MacWhinney, Flatt, & Provost,
1993), version 1.2.5. A custom-designed computer appli-
cation was used to deliver the stimuli and record the
responses for the time production task. Responses were
recorded through the keyboard.
Procedure
All participants refrained from eating for a minimum of
2 hr prior to arriving at the testing site at approximately
noon. Participants then provided informed consent and
received onsite medical screening by a certified neurol-
ogist. They were then administered the neuropsycho-
logical tests, the choice RT task baseline session, and
two time production task baseline sessions (one for each
of two target intervals), in that order. After this, partic-
ipants were administered either 200 mg of levodopa
with 50 mg of carbidopa (i.e., Sinemet 100/25  2) or
two tablets of a placebo, randomly determined, in a
double-blind fashion. Following a 1-hr delay, participants
were given the retesting sessions for the choice RT task
and time production of the two target intervals.




Choice RT task sessions consisted of 30 trials in one
block. The baseline and retest sessions were identical. A
warning signal (‘‘+’’) appearing in the center of the
screen indicated the beginning of a trial. Five hundred
milliseconds after the warning signal appeared, it was
replaced by a number ranging from 1 to 4. Participants
were instructed to press the ‘‘z’’ key with their left
middle finger if the number is ‘‘1,’’ the ‘‘x’’ key with
their left index finger if the number is ‘‘2,’’ the ‘‘.’’ key
with their right index finger if the number is ‘‘3,’’ and
the ‘‘/’’ key with their right middle finger if the number
is ‘‘4.’’ Participants were told to select their responses as
quickly and accurately as possible. Feedback messages
indicating if the response was ‘‘Correct’’ or ‘‘Incorrect’’
appeared 250 msec after the clearing of stimulus and
stayed on the screen for 1.25 sec. Alternatively, the
feedback read ‘‘Sorry, ran out of time’’ if the participant
failed to respond after 2000 msec.
Time Production
The time production task was a variant of the human PI
task (Rakitin, Gibbon, et al., 1998) that included delayed
free-recall retesting sessions without feedback (Rakitin,
Stern, et al., 2005; Malapani, Deweer, et al., 2002).
Production of the 6- and 17-sec target intervals occurred
in separate blocks. The order in which the intervals were
tested was counterbalanced across participants within
group.
The baseline session for each interval consisted of
80 trials. The first 10 ‘‘fixed-time’’ trials demonstrated
the target interval. On each trial, a blue square was
presented until the target interval had elapsed, at which
time it turned magenta for 1 sec and then terminated.
Participants were instructed to remember the duration
of the blue square. The next 10 ‘‘peak-interval’’ (PI)
trials began with the presentation of the blue square.
Participants responded on each trial with a bout of at
Table 4. Participant Demographics
Aged Young
Age range 60–86 18–35
Age 71.2 ± 7.6 24.4 ± 4.4
% Female 53.125 53.125
Education 14.8 ± 2.8 15.3 ± 2.1
UPDRS 0.52 ± 0.25 0 ± 0
mMMSE 54.4 ± 2.7 55.4 ± 1.9
DRS 141.6 ± 1.9 142.9 ± 1.2
Note: Values for age, education, UPDRS, mMMSE, and DRS are the
mean ± standard error. Education is in years.
384 Journal of Cognitive Neuroscience Volume 18, Number 3
least four space bar presses that was supposed to be
centered on the anticipated end of the target interval.
The time of the first keypress is referred to as the ‘‘start’’
time and the time of the last keypress is referred to as
the ‘‘stop’’ time. Following the response, the partici-
pants were shown feedback in the form of a graph
indicating their response times relative to the target
interval, and whether all responses were within 10% of
the target interval. These trials were considered practice
and were not included in the data analysis. The remain-
ing 60 trials consisted of 30 PI trials with feedback, 15 PI
without feedback, and 15 fixed-time trials.
The retest sessions for each interval consisted of
60 peak trials without feedback. The short and long
intervals were tested in separate blocks and in the same
order as the baseline session. There were no fixed-time
trials (i.e., further demonstrations of the target intervals)
or practice trials preceding either block. Before each
block, participants were instructed to reproduce either
the long or the short interval from the baseline session.
For the entire procedure, participants were instructed
to refrain from counting or tapping. To further discour-
age counting, random digits were intermittently super-
imposed over the blue square. Interdigit times were
determined randomly using two uniform distributions,
200–700 and 1300–1800 msec. All trials included the
digit distracters.
Analysis
The mean of the start and stop times (i.e., the ‘‘middle’’)
summarized time production performance for each PI
trial (with or without feedback). The median (MD) and
the NPCV4 (i.e., the {interquartile range/1.348}/MD) of
the trial middles summarized time production within
each Subject  Duration  Session condition. The MD
was used to test hypotheses concerning production
accuracy, or how close productions were to the target
interval on average. The NPCV was used to test hypoth-
eses concerning precision, or intraindividual variability,
including the scalar property of timing variability, which
predicts that target interval duration should not affect
the NPCV. Hypotheses were tested using univariate
ANOVA models. Each model included two between-
participant factors, age group and drug group, and two
within-participant factors, target interval and session,
in a full-factorial design. Models including the order
of testing of the two target intervals (as a between-
participants factor) did not produce significant main or
interaction effects, and this factor was dropped from
the analyses.
The MD, NPCV, and percent correct (%COR) summa-
rized choice RT performance within each Subject 
Session condition. Hypotheses were tested using univar-
iate ANOVA models. Each model included two between-
participant factors, age group and drug group, and one
within-participant factor, session, in a full-factorial design.
Two additional analyses were run for each task in
order to examine the influence of side effects. One
analysis used the standard model for each task, but
excluded those participants who exhibited nausea dur-
ing the retesting session. The other analysis subdivided
the levodopa group participants into those that did or
did not complain of nausea at any time after being given
the drug. This analysis dropped drug group from the
analysis and substituted nausea group as a between-
participants factor.
In order to explore further possible functional rela-
tionships between RT and time production task perform-
ance, we examined the correlations between RT and
time production performance. Difference scores (base-
line  retest) were computed from individuals’ RT,
short-interval time production, and long-interval time
production medians. Correlations between the RT and
the long-interval time production change scores and the
RT and short-interval change scores were computed by
age group, drug group, as well as the four groups of the
Age group  Drug group interaction. Individuals ex-
pressing nausea during the retesting session were ex-
cluded from the analysis.
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Notes
1. The current use of the term ‘‘time production’’ is intended
to distinguish tasks in which timing is assessed by measuring
response latency from ‘‘time perception’’ tasks where partic-
ipants make categorical timing responses, such as in the bisec-
tion procedure (e.g., Allan & Gibbon, 1991). This definition
differs from an older (e.g., Woodrow, 1951), more specific, and
perhaps more common usage where time production refers to
a task in which the participant generates a response with a la-
tency matched to an interval stated in clock time (Allan, 1979).
2. The term ‘‘time basis’’ replaces the older term ‘‘clock
stage.’’ This substitution is intended to make a clear distinc-
tion between one stage of the information processing of in-
tervals including the pacemaker, switch, and accumulator,
and all cognitive processes necessary for interval timing re-
ferred to together as the ‘‘internal clock.’’
3. Rammsayer also used Madopar instead of Sinemet. The
two drugs differ in the additive used to reduce associated
nausea. Madopar adds benserazide hydrochloride, whereas
Sinemet adds carbidopa. This difference is unlikely to have
contributed to the studies’ different outcomes.
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4. In order to avoid mixing parametric and nonparametric
summary statistics, we generate a distribution relative scale
parameter, the NPCV, by substituting the robust estimators of
spread (the interquartile range) and central tendency (the MD)
into the more familiar equation for the parametric scale
estimator, the CV (or the standard deviation/the mean). In
order to make the NPCV and the CV comparable in magnitude,
the interquartile range has to be divided by 1.348 because the
interquartile range accounts for a larger proportion of the
normal distribution than does the standard deviation. That is,
for a normal population, the standard deviation/interquartile
range = 1.348.
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